| Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes P Momtaz, CA O’Connor, JF Chou, M Capanu, W Park, C Bandlamudi, ... Cancer 127 (23), 4393-4402, 2021 | 40 | 2021 |
| Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice W Park, CA O'Connor, C Bandlamudi, D Forman, JF Chou, S Umeda, ... Clinical Cancer Research 28 (21), 4782-4792, 2022 | 20 | 2022 |
| Pancreatic Cancer: BRCA Targeted Therapy and Beyond F Keane, CA O’Connor, W Park, T Seufferlein, EM O’Reilly Cancers 15 (11), 2955, 2023 | 16 | 2023 |
| Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination … W Park, C O'Connor, JF Chou, C Schwartz, AM Varghese, M Larsen, ... Journal of Clinical Oncology 41 (16_suppl), 4140-4140, 2023 | 10 | 2023 |
| Leptomeningeal disease in pancreas ductal adenocarcinoma: a manifestation of longevity CA O’Connor, JS Park, T Kaley, B Kezlarian, M Edelweiss, TJ Yang, ... Pancreatology 21 (3), 599-605, 2021 | 6 | 2021 |
| Lynch syndrome and somatic mismatch repair variants in pancreas cancer CA O’Connor, E Harrold, D Lin, H Walch, A Gazzo, M Ranganathan, ... JAMA oncology 10 (11), 1511-1518, 2024 | 4 | 2024 |
| Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease F Keane, JF Chou, H Walch, J Schoenfeld, A Singhal, D Cowzer, ... JNCI: Journal of the National Cancer Institute 116 (9), 1429-1438, 2024 | 3 | 2024 |
| Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses. CA O'Connor, E Harrold, YT Lin, HS Walch, A Gazzo, SR Kane, F Keane, ... Journal of Clinical Oncology 42 (16_suppl), 4144-4144, 2024 | 2 | 2024 |
| Harnessing patient life stories to engage medical trainees in strengthening veteran-provider relationships SK Thareja, J Laridaen, I Puls, C O’Connor, S Jovaag, T Ringler, ... Medical Science Educator 33 (5), 1155-1163, 2023 | 2 | 2023 |
| A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer. R Tuli, F Keane, JD Schoenfeld, C O'Connor, C White, JF Chou, ... Journal of Clinical Oncology 41 (16_suppl), 4164-4164, 2023 | 2 | 2023 |
| Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC). F Keane, L Saadat, C O'Connor, JF Chou, AR Brannon, D Cowzer, ... Journal of Clinical Oncology 41 (16_suppl), 4154-4154, 2023 | 2 | 2023 |
| A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC). F Keane, JD Schoenfeld, F Crowley, CA O'Connor, C White, C Schwartz, ... Journal of Clinical Oncology 41 (4_suppl), 725-725, 2023 | 1 | 2023 |
| Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO). F Keane, F Balogun, C O'Connor, F Crowley, A Chan, D Cowzer, JF Chou, ... Journal of Clinical Oncology 41 (4_suppl), 685-685, 2023 | 1 | 2023 |
| Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort F Keane, C O’Connor, D Moss, JF Chou, MA Perry, F Crowley, P Saxena, ... JNCI: Journal of the National Cancer Institute 117 (3), 496-506, 2025 | | 2025 |
| Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes. F Keane, D Moss, CA O'Connor, M Perry, JF Chou, F Crowley, P Saxena, ... Journal of Clinical Oncology 42 (16_suppl), 4170-4170, 2024 | | 2024 |
| Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC) E Harrold, CA O'Connor, D Lin, A Gazzo, H Walch, M Ranganathan, ... Cancer Research 84 (2_Supplement), B042-B042, 2024 | | 2024 |
| Abstract B045: Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer W Park, S Umeda, C O'Connor, H Zhang, R Sharma, A Richards, Y Zhu, ... Cancer Research 84 (2_Supplement), B045-B045, 2024 | | 2024 |
| Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK). P Momtaz, CA O'Connor, JF Chou, M Capanu, KH Yu, AM Varghese, ... Journal of Clinical Oncology 38 (4_suppl), 708-708, 2020 | | 2020 |